Check SUne website it contradicts what you are saying. Please get the facts correctly. I too belive Sune is a screamimg buy.
Citigrl truthdetective is right unless you can show the thread. The conversion price is $14.62
It would be nice to see if insiders started buying the stock. What a vote of confidence it would give to shareholders and employee's. They continue to sell stock. Ted and the compensation committee should stop giving stock options to Board members and company executives. It sends the wrong message to shareholders when they continue to sell stock.
I believe we saw major shake when it hit 7.13 intraday and closed up two weeks ago. Any push back by shorts will be a gift here since it will come back stronger. I will look to add to my position on any pull back of significance.
Reason I bring this up is Ted can use this when looking at cross licensing deals in buying or selling other companies products. We all agree the stock price should be higher, but the launch was as successful as any hospital injectable that has been launched in the last 10 years.
I have not seen any upgrades yet, however investment firms like to build up their inventory before they come out wit buy recommendations. People short this stock now will get burned and push the stock higher.
Discount out by 6%, because those are WAC numbers, and that is not accurate. Cadx will end the year over $10 dollars. I believe a takeover brings $21-22 dollars.
They are desperate, and this was a very concerted effort by a few traders to push this stock down. I believe this stock will be green by the end of the day. You can see smart money buying here.
I belive this stock will end the year up over $10 dollars, setting the stage for a fabulous 2014. A buyout is a possability, unless Ted is able to obtain some drugs. This is well on its way to being a $500 million dollar drug in 3 years or less.
Upgrades will come as early as Monday, do not sell your stock. Watch the shorts cover because they do not want to hold the stock over the weekend. Let's see them get a taste of their own medicine. It may be painful perhaps they will use Ofirmev LOL
You can see the shorts are getting desperate by all the negative posts on this MB. Stockfraud is just that a stock fraud. I donot see management selling any more shares lately.
From an execution stand point Cadence has delivered spectacular growth over the last two years. If this were a biotech stock it would be close to 100 dollars. However the two patent litigations have kept this stock down, while management has delivered and tempered enthusuasm in short they have been conservative. Next week we will begine to get upgrades. I hope Ted is recouping lawyers fee's for this patent litigation brought on by Perrigo and Excela. For the rest of the year it shouldn't be how low will Cadence go, but how high will it go. Shareholders should be paid for sticking by management and believing in Ofirmev. Short bagholders should pay dearly every time they short this stock. I still see Cadence doing around $150-$165 million next year.
TThat was a typo in the year sales figure of $125 million EOMat was a typo on the $125 million EOM
That is a new record for quarterly sales. I believ the third quater will now come in around $33 -35 million. It is too early to tell how the Black Box warning will hurt sales. Maybe Ted will give us some guidance. I believe it will be a moot point. I see Totatl sales coming in around $125 million.
It is absurd to see the FDA request this Black Box Warning. Most drugs out there should have a black box warning. Lipitor, Zocor, Crestor, Aspirin and the list goes on and on. You can get elevated liver levels after getting any dose of acetaminophen. Why is the FDA asking for this now. The reason being is they are trying to show that no one at the FDA is asleep at the wheel. This Black Box will not effect the growth of Ofirmev if Cadence is proactive in telling physicians that elevated liver enzymes have always been there with acetaminophen usage, long before the IV version hit the market. Focus on the earnings I believe on Monday October 28th we will see how they did for September. Anything over 11 million will be very bullish for the company.
This board is very apathetic. They should wake up and smell the coffee on this one. Next year it will be a big winner and one of the streets favorite stocks.
You can take this date down and throw it back at me in 1st quarter 2015, but I am throwing down the gauntlet and saying Cadence will earn $0.65/share next fiscal year. What should the stock be if you are buying on trailing 12 months of earnings. With a multiple of 20 , I believe the stock should be $13.00. I believe the stock deserves a higher multiple because it is still growing.
Two months down and I believe September so far has been a better month. See the third quarter coming in about $32 million. See the fourth quartter around $36.8 million. Will see year around $118 million conservitively.. I think we are beginning to see excellent growth month over month, and quarter over quarter.
If they get Canadian approval early fourth quarter, that may may push total sales to $135 million or better for the year. That is considered break even for the company. I believe there is a 10% chance they can reach $135 without Canada. I believe the stock should be low teens late fourth or early first quarter 2014. I believe next year will be a breakout year for Cadence. It is still a potential buyout, because this drug gets patients out of the hospital a lot quicker. Opiates have so many side effects, and any hospital not willing to use it will open up the risk of lawsuits when the public gets wind of the benefits of Ofirmev versus opiates.
We will know in two weeks how August turned out. If we do another $10 million we will be looking at around $31-32 million for the third quarter. The fourth quarter is traditionally one of the busier quarters with respect to surgery because people tend to get elective surgery done in the last quarter, prior to possible their insurance changing or because they put tax free money aside to do elective surgery, and they need to use it. The fourt quarter should be around $35 million, but can be as high as $40 million. Thats if this quarter comes in at $31-32 million. I still think the range is $115-125 million for the year..